Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 4

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Authors Victor G Vogel

Published 5 December 2008 Volume 2008:3(4) Pages 601—609

DOI http://dx.doi.org/10.2147/CIA.S3344

Review by Single-blind

Peer reviewer comments 2

Victor G Vogel

The University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USA

Abstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease risk, but it has no significant effect on the risk of primary coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% confidence interval [CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer.

Keywords: raloxifene, osteoporosis, breast cancer risk reduction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles

Alarifi S, Ali D, Alkahtani S, Verma A, Ahamed M, Ahmed M, Alhadlaq HA

International Journal of Nanomedicine 2013, 8:983-993

Published Date: 7 March 2013

Synthesis, characterization, and in vivo efficacy evaluation of PGG–docetaxel conjugate for potential cancer chemotherapy

Yang D, Van S, Shu Y, Liu X, Ge Y, Jiang X, Jin Y, L Yu

International Journal of Nanomedicine 2012, 7:581-589

Published Date: 3 February 2012

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:353-363

Published Date: 23 June 2011

Prevention of atherosclerosis in patients living with HIV

Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff, Han Xiao

Vascular Health and Risk Management 2009, 5:287-300

Published Date: 26 March 2009

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction

Giovanni Melandri, Fabio Vagnarelli, Daniela Calabrese, Franco Semprini, Samuele Nanni, Angelo Branzi

Vascular Health and Risk Management 2009, 5:249-256

Published Date: 26 February 2009

Once-daily treatment of ADHD with guanfacine: patient implications

Brandon C Strange

Neuropsychiatric Disease and Treatment 2008, 4:499-506

Published Date: 6 June 2008

Hyaluronic acid gel fillers in the management of facial aging

Fredric S Brandt, Alex Cazzaniga

Clinical Interventions in Aging 2008, 3:153-159

Published Date: 7 March 2008